PDF(Pubmed)
Abstract：
Both clonal plasma cell and myeloid disorders occur more frequently with age. Patients with concurrent clonal plasma cell and myeloid disorders (CPCMD) can present clinical and therapeutic challenges. In this single-institution cohort of patients with CPCMD (n = 18), we abstracted clinically relevant themes. A majority of patients (12/18) were treated with clone-directed therapies and three received treatment targeting both clones. Treatment of clones with targetable genetic lesions or those causing end-organ complications should be prioritized. Simultaneous treatment of both clones can be safe but is best done in a stepwise manner. Further study of patients with dual clonal processes is warranted.
摘要：
随着年龄的增长，克隆浆细胞和髓样疾病的发生频率更高。同时患有克隆性浆细胞和髓样疾病（CPCMD）的患者可能会面临临床和治疗挑战。在这个单机构CPCMD患者队列中(n=18)，我们提取了临床相关主题.大多数患者（12/18）接受了克隆定向治疗，三名患者接受了靶向两个克隆的治疗。应优先治疗具有可靶向遗传病变或引起终末器官并发症的克隆。同时处理两个克隆可以是安全的,但最好以逐步方式进行。有必要对双克隆过程的患者进行进一步研究。
